You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Details for Patent: 8,771,733

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,771,733 protect, and when does it expire?

Patent 8,771,733 protects ISENTRESS and ISENTRESS HD and is included in two NDAs.

This patent has eleven patent family members in eight countries.

Summary for Patent: 8,771,733

Scope and claims summary:

Title:	Pharmaceutical composition containing an anti-nucleating agent
Abstract:	Pharmaceutical compositions suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a drug compound in the form of a salt, wherein the drug salt is characterized by conversion to a less soluble form of the drug compound under certain pH conditions, and an anti-nucleating agent.
Inventor(s):	Cruanes Maria T., Xu Wei, Artino Laura M., Zhu Honggang
Assignee:	Merck Sharp & Dohme Corp.
Application Number:	US11792190
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 8,771,733

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Msd Sub Merck	ISENTRESS	raltegravir potassium	TABLET, CHEWABLE;ORAL	203045-002	Dec 21, 2011		RX	Yes	Yes	8,771,733	⤷ Subscribe	Y	Y		TREATMENT OF HIV INFECTION	⤷ Subscribe
Msd Sub Merck	ISENTRESS	raltegravir potassium	TABLET;ORAL	022145-001	Oct 12, 2007		RX	Yes	Yes	8,771,733	⤷ Subscribe	Y	Y		TREATMENT OF HIV INFECTION	⤷ Subscribe
Msd Sub Merck	ISENTRESS HD	raltegravir potassium	TABLET;ORAL	022145-002	May 26, 2017		RX	Yes	Yes	8,771,733	⤷ Subscribe	Y	Y		TREATMENT OF HIV INFECTION	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,771,733

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005311714	⤷ Subscribe
Canada	2588465	⤷ Subscribe
China	101068533	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.